Analysts eye Ranbaxy results, commentary

Shares of Ranbaxy will be in focus on Wednesday, as the company is scheduled to announce its October-December quarter financial performance. Analysts’ views are divided with some expecting the company to post a profit of about ₹130 crore and others believing it could report a loss. However, more than its earnings, the Street will look to the management’s comments on the timeline for resolving regulatory problems, launching Diovan and the anti-viral drug Valcyte, in the US. The stock has gained about two per cent on Tuesday at ₹321.75.